Evidence map›Paper›PMID 31292197›Full record

SynthesisJournal of the American Society of Nephrology : JASN2019

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Lesley A Inker, Hiddo J L Heerspink, Hocine Tighiouart, Andrew S Levey, Josef Coresh, Ron T Gansevoort, Andrew L Simon, Jian Ying, Gerald J Beck, Christoph Wanner and 5 more

Registry-linked trialOpen access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07719621 (Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D), which is not on this map. Cited by 158 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 12 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07719621 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D

TypeobservationalSponsorAeterna Medical Solutions SLRan2026 to 2026Enrolled50,000ConditionsCKD - Chronic Kidney Disease, Diabetes Mellitus Type 2
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 12 syntheses or guidelines pooled it, 281 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Trial
  14. Trial
  15. Trial
  16. The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  17. Trial
  18. Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.Clinical journal of the American Society of Nephrology : CJASN · 2021
    Trial
  19. Trial
  20. Trial

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 5 countries.

Lesley A InkerDivision of Nephrology and LInker@tuftsmedicalcenter.org.
Hiddo J L HeerspinkDepartments of Clinical Pharmacy and Pharmacology and.
Hocine TighiouartThe Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts.
Andrew S LeveyDivision of Nephrology and.
Josef CoreshDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Ron T GansevoortNephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Andrew L SimonDivision of Nephrology and.
Jian YingDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Gerald J BeckDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Christoph WannerDivision of Nephrology, University Hospital of Würzburg, Würzburg, Germany.
Jürgen FloegeDivision of Nephrology, RWTH Aachen University, Aachen, Germany.
Philip Kam-Tao LiDivision of Nephrology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong; LInker@tuftsmedicalcenter.org.
Vlado PerkovicGeorge Institute for Global Health, University of New South Wales, Sydney, Australia; and.
Edward F VoneshDepartment of Preventive Medicine, Division of Biostatistics, Northwestern University, Chicago, Illinois.
Tom GreeneDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Pediatric Nephrology of Alabama · USUniversity of Utah · USCleveland Clinic · USJohns Hopkins University · USPrince of Wales Hospital · CNRWTH Aachen University · DEThe George Institute for Global Health · AUTufts Medical Center · USTufts University · USUniversitätsklinikum Würzburg · DEUniversity Medical Center Groningen · NL

Funding

Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
NCATS NIH HHS UL1 TR002544
6 · The paper itself

Abstract

backgroundSurrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the end of a randomized, controlled trial as an end point in CKD because it is not clear whether small changes in the GFR slope will translate to clinical benefits.

methodsTo assess the use of GFR slope as a surrogate end point for CKD progression, we performed a meta-analysis of 47 RCTs that tested 12 interventions in 60,620 subjects. We estimated treatment effects on GFR slope (mean difference in GFR slope between the randomized groups), for the total slope starting at baseline, chronic slope starting at 3 months after randomization, and on the clinical end point (doubling of serum creatinine, GFR<15 ml/min per 1.73 m

resultsAcross all studies, the treatment effect on 3-year total GFR slope (median

conclusionsWith large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.

Indexed as

Disease ProgressionGlomerular Filtration RateBayes TheoremBiomarkersCreatinineHumansKidney Failure, ChronicPredictive Value of TestsRandomized Controlled Trials as TopicRenal Insufficiency, ChronicBiomarkersCreatininechronic kidney diseaseend stage kidney diseaseGFRmeta-analysisrandomized controlled trials

Identifiers

PMID31292197
PMCPMC6727261
OpenAlexW2962169757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.